US equities |
AAPL $349.51 ▲+5.31% NVDA $200.13 ▼-3.17% MSFT $555.80 ▲+6.68% MU $795.23 ▼-7.00% AMZN $266.03 ▲+6.12% AMD $488.78 ▲+1.01% META $630.00 ▲+1.44% SPCX $135.92 ▼-3.81%
FinancialContent

Scinai Immunotherapeutics Ltd. - American Depositary Shares (NQ:SCNI)

0.4488 -0.0212 (-4.51%)
Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scinai Immunotherapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights CDMO Contract Growth, $5.3 Million Financing and Extended Operating Runway
Via Investor Brand Network
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $4 Million Private Placement and Warrant Inducement Transaction
Via Investor Brand Network
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $5.1 Million Development and Clinical Manufacturing Agreement
Via Investor Brand Network
News headline image
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
Via AB Newswire
Topics Artificial Intelligence
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Refocuses R&D Portfolio on NanoAb Platform and CDMO Growth
Via Investor Brand Network
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2026 Results, Advances Expanded U.S. Clinical Manufacturing Program
Via Investor Brand Network
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Eran Kuratz to Lead CDMO Supply Chain, Business Process Administration
Via Investor Brand Network
Topics Economy
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Eilon Elmalem as Head of Yavne CDMO Facility
Via Investor Brand Network
News headline image
Kartoon Studios (NYSE American: TOON) Surges on Volume as Media Consolidation Accelerates Following Paramount-Warner Bros. Approval
Via AB Newswire
Topics Intellectual Property
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $2.61M Private Placement and Warrant Inducement
Via Investor Brand Network
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Nasdaq Notice on Minimum Bid Price Compliance
Via Investor Brand Network
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Amends PinCell Option Agreement and Submits €12M SMART Path Grant Application
Via Investor Brand Network
Topics Economy
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Expanded IIA Grant Support for Robotic Aseptic Fill & Finish Platform
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO to Co-Lead Biopharma Manufacturing Roundtable During HealthIL Week 2026
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2025 Results and Strengthened Cash Position
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award
Via Investor Brand Network
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights Growth and SEPA Funding Ahead of BIO 2025 CEO Participation
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders
Via Investor Brand Network
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell
Via Investor Brand Network
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Present at BIO-Europe Spring 2025
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement
Via Investor Brand Network
Layoffs, Upheaval at CDC Trigger Fears on Handling Disease Outbreaks
Via Investor Brand Network
Topics Government Workforce
Biomaterial Modification Could Yield Better Cancer Therapies, Study Finds
Via Investor Brand Network
New Trump Admin Could Drastically Change Research on Infectious Diseases
Via Investor Brand Network
Topics Government
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences
Via Investor Brand Network
Researchers Identify Protein That Makes Cancer Evade Cell Therapy
Via Investor Brand Network
< Previous 1 2 3 4 Next >